<DOC>
	<DOCNO>NCT00062660</DOCNO>
	<brief_summary>To provide early access tipranavir evaluate safety tolerance tipranavir combine low dose ritonavir patient progressive , HIV-1 disease fail intolerant currently approve treatment HIV infection , unable participate another tipranavir control clinical trial urgent need anti-HIV treatment .</brief_summary>
	<brief_title>Tipranavir Patients With Progressive , Systemic HIV-1 Disease Who Have Failed Are Intolerant Currently Approved Treatments HIV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Inclusion criterion : Patients aho positive serology HIV antibody test confirm Western blot , p24 antigen assay , HIV1 RNA HIV culture highly pretreated virus resistant multiple protease inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>